

Curriculum Vitae

Family name	Van der Hilst
Name	Jeroen Cornelis Hendrik
Nationality	Dutch
Address	Department of Infectious diseases and Immunity, Jessa Hospital, Stadsomvaart 11, 3500, Hasselt, Belgium
Email	jeroen.vanderhilst@jessazh.be jeroen.vanderhilst@uhasselt.be

PROFESSIONAL EXPERIENCE

2002-2009	Resident internal medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
2009-2011	Fellow Infectious Diseases, University Medical Centre Utrecht, Utrecht, the Netherlands
2011- present	Consultant physician infectious diseases and immunity, Jessa Hospital, Hasselt, Belgium
2016-present	Chair Jessa Travel Clinic, Jessa Hospital, Hasselt, Belgium
2012 – 2015	Visiting Professor, BIOMED, University of Hasselt, Belgium
2015-present	Assistant professor of Immune Pathology, University of Hasselt, Belgium

PhD thesis

Hyper IgD syndrome and type AA amyloidosis, January 2009, Radboud University Nijmegen, Nijmegen, the Netherlands

List of publications

Smits BW, Van der Hilst JC. Hypo- en agammaglobulinemie
NTvG-S. 2000 3(1):4-6

Van der Hilst JC, Smits BW, van der Meer JW. Hypogammaglobulinaemia: cumulative experience in 49 patients in a tertiary care institution.
Neth J Med. 2002;60(3):140-7.

Van der Hilst JC, Simon A, Drenth JP. Molecular mechanisms of amyloidosis.
N Engl J Med. 2003;349(19):1872-3;

Bodar EJ, Simon A, van der Hilst JC, van Deuren M. Two patients with recurrent fever and wine red discolouration of the eyelids.
Neth J Med. 2004 Apr;62(4):119-20, 139

Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, Drenth JP. Beneficial response to interleukin 1 receptor antagonist in traps.
Am J Med. 2004;117(3):208-10

Van der Hilst JC, Drenth JP, Bodar EJ, Bijzet J, van der Meer JW, Simon A. Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome.
Amyloid. 2005 ;12:115-119

Van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis
Clin Exp Med. Oct 2005;(3): 87-98

Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.
Neth J Med 2005;(7): 260-264

de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome
Ann Rheum Dis Apr 2006;65 (4): 542-544

Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A. Defective apoptosis of peripheral blood lymphocytes in hyper-IgD and periodic fever syndrome.
Blood. Mar 2007;15;109(6):2416-8

Van der Hilst JC, van der Meer JW, Drenth JP, Simon A. AL amyloidosis enhances development of AA amyloidosis.
British J Dermatol Apr 2007;156(4):748-9

Van der Hilst JC, Kluge-Beckerman B, Bodar EJ, van der Meer JW, Drenth JP, Simon A. Lovastatin inhibits formation of AA amyloid.
J Leukoc Biol. May;83(5):1295-9.

Van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis.
Rheumatology (Oxford). 2008 Nov;47(11):1651-4

Van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, Simon A & the international HIDS study group. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with mutation-positive Hyper-Immunoglobulinemia D Syndrome.
Medicine(Baltimore) 2008 Nov;87(6):301-10

Van der Hilst JC, Kluge-Beckerman B, van der Meer JW, Simon A. Cathepsin D activity protects against development of AA amyloidosis.
Eur J Clin Invest 2009 May;39(5): 412-16

Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G. A Clinical Criterion to Exclude the Hyperimmunoglobulin D Syndrome (Mild Mevalonate Kinase Deficiency) in Patients with Recurrent Fever. *J Rheumatol.* 2009 May;39(5):412-6.

Van der Hilst JC, Frenkel J. Hyperimmunoglobulin D syndrome in childhood. *Curr Rheumatol Rep.* 2010 Apr;12(2):101-7.

Van der Hilst JC. New insights in the pathogenesis of type AA amyloidosis. *TSW Journal*, 2011 Mar 7;11:641-50.

Van der Hilst JC, Gyssens I. De autoinflammatoire syndromen, een update. *Tijdschrift voor Geneeskunde*, 2012;68(13):648 – 654

Bakelants E, van der Hilst J, Corluy L, Achten R, Gyssens I, Messiaen P. The diagnostic tangle of pyoderma gangrenosum: a case report and review of the literature. *Neth J Med*, 2014; 10: 541-544

Van der Hilst JC, Messiaen PE. Een patiënt met rode oortjes. *Tijdschr. voor Geneeskunde* 2015, 71,(6): 409-412

Van der Hilst JC, Wisanto E, Messiaen PE. Een opspelend litteken. *Tijdschr. voor Geneeskunde* 2015, 71,(14-15): 969-71

De Boeck C, Dehollogne C, Dumont A, Spierenburg M, Heijne M, Gyssens I, Vanrompay D, Van der Hilst J. Managing a cluster outbreak of psittacosis in Belgium linked to a pet shop visit in The Netherlands. *Epidemiol Infect.* 2016 Jun;144(8):1710-6

Messiaen PE, Gyssens IC, Van der Hilst JC, Persistierende artalgiën na een verblijf in Bolivia: de grote chikungunyavirus-epidemie op het westelijk halfrond. *Tijdschr. voor Geneeskunde* 2016, 72,(1): 36-40

P.E.A. Messiaen, K. Peeters, M.J.A. van Esbroeck, E.J.L. Bijmens, K.K. Wouters, I.C. Gyssens, J.C.H. van der Hilst. A 47-year-old woman with fever and periorbital oedema. *Neth J Med* 2016; 74(2): 96

Van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. *Biologics : Targets & Therapy.* 2016;10:75-80

Harrison S, McGonagle D, Nizam S, Jarrett S, van der Hilst J, McDermott M, Savic S. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. *JCI Insight.* 2016 May 5;1(6)

Westhovens IM, Vanden Abeele M, Messiaen PE, van der Hilst JC. Systemic BCG infection in a patient with pancytopenia and fever 9 years after intravesical BCG administration for bladder cancer. *BMJ Case Rep* 2016. doi:10.1136/bcr-2016-215599

Messiaen P, Cambier JP, van der Hilst JC. Een 57-jarige patiënt met koorts, focaal erytheem en een progressieve pijnlijke parese van de onderste ledematen. *Tijdschr. voor Geneeskunde* 2016; 72(13) 782-786

Van Mechelen M , Messiaen PE, van der Hilst JC. A salt-water aquarium can be a dangerous hobby: A case report of palytoxin intoxication after dermal contact with poisonous coral. *Toxicology International*. 2016 Sept-Dec;23(3)

Messiaen P, Forier A, Vanderschueren S, Theunissen C, Nijs J, Van Esbroeck M, Bottieau M, De Schrijver K, Gyssens I, Cartuyvels R, Dorny P, van der Hilst J, Blockmans D. Outbreak of Trichinellosis in Belgium associated with Consumption of Imported Wild Boar Meat. *Euro Surveill*. 2016 Sep 15;21(37).

Messiaen P, Cuyx S, Dejagere T, Gyssens IC, Van der Hilst JC. The role of CD4-cell count as discriminatory measure to guide chemoprophylaxis against *Pneumocystis jiroveci* pneumonia in HIV-negative immunocompromised patients: a systematic review, *Transpl Infect Dis*. 2017 Apr;19(2).

Quintiens J, Vandenabeele ME, Vanderschueren S, van der Hilst J, Messiaen P. Koorts van ongekende oorsprong: het systematisch ontrafelen van een diagnostisch kluwen. *Tijdschr. voor Geneeskunde* 2017; 73(6) 329-335

Mistry A, Savic S, van der Hilst J. Interleukin-1 Blockade: An Update on Emerging Indications. *BioDrugs*. 2017 Jun;31(3):207-221

Messiaen P, Cartuyvels R, Moreels T, Hites M, Oude Lashof A, van der Hilst J Een praktische handleiding voor infectiepreventie bij patiënten die gaan starten met immuunsuppressieve medicatie. *Tijdschr. voor Geneeskunde* 2017; 73(11) 688-693

Baecke C, Gyssens IC, Decoutere L , van der Hilst JC , Messiaen P, Prevalence of drug-drug interactions in the era of HIV integrase 2 inhibitors: a retrospective clinical study. *Neth J Med*. 2017 Jul;75(6):235-240

Tijls L, Messiaen P, van der Hilst J, Madoe V, Melis C, Van Eyken P, Vanmoerkerke I, Janssens F Hepatic schistosomiasis with massive splenomegaly: a case report and literature review, *Acta Gastro-Ent Belg* 2017 *Acta gastroenterol. belg.*, 2018, 81, 93-96

Van Mechelen M, van der Hilst J, Gyssens IC, Messiaen P Mycobacterial skin and soft tissue infections: TB or not TB? *Neth J Med*. 2018 *in press*

Book chapters

J. C. van der Hilst, J. W. van der Meer, and J. P. Drenth, "Autoinflammatory Fever Syndromes" in *Clinical Immunology: Principles and Practice* 3rd ed., edited by Rich R.R. et al (Mosby, St Louis, 2008)

J. C. van der Hilst, J. W. van der Meer, and A. Simon, "Systemic Autoinflammatory Syndromes" in *Clinical Immunology: Principles and Practice* 4th ed., edited by Rich R.R. et al (Expert consult, 2013)

Mulders-Manders CM, van der Hilst J, van der Meer JW, Simon A, "Systemic Autoinflammatory Syndromes" in *Clinical Immunology: Principles and Practice* 5th ed., edited by Rich R.R. et al (Expert consult, 2018)

Van der Hilst J, Drenth J. 'Autoinflammatory syndromes' Chapter 65 in *Pediatric Practice: Infectious Diseases* 2nd ed., edited by Shah, S (McGraw-Hill, 2018)

Publications as collaborating author

Gras L, van Sighem A, Bezemer D, Smit C, Wit F, de Wolf F; ATHENA national observational cohort study. Lower mortality and earlier start of combination antiretroviral therapy in patients tested repeatedly for HIV than in those with a positive first test. *AIDS*. 2011 Mar 27;25(6):813-8.

HIV-CAUSAL Collaboration, Cain LE, Logan R et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study *Ann Intern Med*. 2011 Apr 19;154(8):509-15.

Benard A, van Sighem A Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. *Clin Infect Dis*. 2011 May;52(10):1257-66.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. HIV-CAUSAL Collaboration. *AIDS*. 2012 Aug 24;26(13):1691-705

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. HIV-CAUSAL Collaboration. *Clin Infect Dis*. 2012 May;54(9):1364-72.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. D:A:D Study Group. *J Int AIDS Soc*. 2012 Oct 10;15(2):17426

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. HIV-CAUSAL Collaboration. *AIDS*. 2012 Aug 24;26(13):1691-705.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Julia del Amo, Santiago Moreno, Heiner C Bucher, Hansjakob Furrer, Roger Logan, Jonathan Sterne, et al. in *Clinical infectious* (2012)54(9):1363-72

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Kathy Petoumenos, Signe W Worm, Eric Fontas, Rainer Weber, Stephane De Wit, Mathias Bruyand, et al. in *Journal of the International AIDS Society* (2012).15(2) 17426

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM? Luuk Gras, Ronald B Geskus, Suzanne Jurriaans, Margreet Bakker, Ard van Sighem, Daniela Bezemer, et al. in *PloS one* (2013) 8(5)

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Margalida Rotger, Tracy R Glass, Thomas Junier, Jens Lundgren, James D Neaton, Estella S Poloni, et al. in *Clinical infectious* 2013.57(1) 112-21

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. Lene Ryom, Amanda Mocroft, Ole Kirk, Signe W Worm, David A Kamara, Peter Reiss, et al. in *The Journal of infectious diseases* 2013.207(9)1359-69

Associations between immune depression and cardiovascular events in HIV infection.

Caroline A Sabin, Lene Ryom, Stephane De Wit, Amanda Mocroft, Andrew N Phillips, Signe W Worm, et al. in AIDS (2013)

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. Signe W Worm, Mark Bower, Peter Reiss, Fabrice Bonnet, Matthew Law, Gerd Fätkenheuer, et al. in BMC infectious diseases (2013) 13. 471

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Colette J Smith, Lene Ryom, Rainer Weber, Philippe Morlat, Christian Pradier, Peter Reiss, et al. in Lancet (2014) 384:241-248

Oral presentations and published abstracts

Van der Hilst JC, Simon A, Bodar EJ, van der Meer JW, Drenth JP. Serum amyloid A concentrations and SAA gene polymorphism do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Xth International congress on amyloid and amyloidosis Apr 18-22, 2004, Tours, France

Van der Hilst JC, Bodar EJ, Drenth JP, van der Meer JW, Simon A Resistance of SAA 1.5 to Degradation by MMP-1 as an Explanation for Protection Against Amyloidosis. The Fourth International Congress on the Systemic Autoinflammatory Diseases "FMF and Beyond" Nov 2005 NIH, Bethesda, USA

Van der Hilst JC, Bodar EJ, Drenth JP, van der Meer JW, Simon A. Inhibition of Amyloidosis by Lovastatin The Fourth International Congress on the Systemic Autoinflammatory Diseases "FMF and Beyond" Nov 2005 NIH, Bethesda, USA

Van der Hilst JC, Bodar EJ, Drenth JP, Van der Meer JW, Simon A. AL amyloidosis enhances development of AA amyloidosis. XIth International Symposium on Amyloidosis, Nov 2006 Woods Hole, USA

Van der Hilst JC, Drenth JP, Van der Meer JW, Simon A Patients with AA amyloidosis have a higher monocytic cathepsin B:D ratio. Nov 2006 Woods Hole, USA

Van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, Simon A & international HIDS study group. Follow-up, clinical features, and quality of life in 103 patients with HyperImmunoglobulin D syndrome. The fifth international congress on familial Mediterranean fever and systemic autoinflammatory diseases. April 2008, Rome, Italy

Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G, A clinical prediction rule to exclude the hyperimmunoglobulin D syndrome in patients with recurrent fever. The fifth international congress on familial Mediterranean fever and systemic autoinflammatory diseases. April 2008, Rome, Italy

Van der Hilst JC, The autoinflammatory hereditary disorders.
Rare causes of fever: *from autoinflammatory to lysosomal diseases* 9 December 2009
Policlinico A. Gemelli Università Cattolica del Sacro Cuore, Rome, Italy

Van der Hilst JC, New insights in the pathogenesis of type AA amyloidosis, Autoinflammation 2010, the 6th International Conference on FMF and other Autoinflammatory Diseases, 2010 September, Amsterdam, the Netherlands

Van der Hilst JC. Too much immunoglobulin: Diseases relevant to the Rheumatologist. The Hyper IgD syndrome: a cause of periodic fever. EULAR, May 2011, London, United kingdom

Van der Hilst JC. De IMpact of AGEing on Innate immunity (IMAGINE) studie: verminderde cytokineproductie na stimulatie door pneumococcen bij gezonde oudere vrijwilligers. Geriatriedagen februari 2013, Den Bosch, the Netherlands

Soentjens P. Van der Hilst JC. Diagnosis of a Travel-related *Schistosoma mansoni* Infection in a cohort of 21 Subjects. Congress of the International Society of Travel Medicine, May 2013, Maastricht

Ngo B, Cartuyvels R, Magerman K, Gyssens I, van der Hilst J, Mewis A. Hepatitis A Serologic Screening in Travellers: An evaluation '10 years after' Congress of the International Society of Travel Medicine, May 2013, Maastricht

Van Der Hilst J, De Boeck C, Vanrompay D, Dehollogne C. Managing a Cluster Outbreak of Psittacosis. ID Week, 8-12 October 2014, Philadelphia, USA

Van der Hilst JC, Lijnen A. The effect of Anakinra on Quality-of-Life in a family with colchicine-resistant FMF. 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases, October 2015, Dresden, Germany

Van der Hilst JC. 'it is all in the game' Interactive case discussion. Current Topic in Infectious Diseases, January 2016, Grindelwald, Austria

Messiaen P, Bottieau E, Van Esbroeck M, Nijs, J, Dorny P, Van der Hilst J, Vanderschueren S, Blockmans D, Forier A. Managing a large Outbreak of Trichinellosis in Belgium associated with Consumption of Imported Wild Boar Meat. IDWeek 2015 October 10. San Diego USA.

Messiaen P, Baecke C, van der Hilst J. Prevalence of drug-drug interactions involving antiretroviral treatment: impact of the integrase inhibitor class. HIV drug Therapy. October 2016 Glasgow, UK

Frenkel J, Anton J, van der Hilst J *et al.* Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial. ACR Annual meeting. November 2016, Washington, USA

Van der Hilst J, Hites M. Screening and preparing the future immunocompromised patient. Annual Congress of the Belgian Society of Internal Medicine. 2016 December 15, Brussels, Belgium

Van der Hilst J. Meet-the-expert: autoinflammation. 29th Dutch Internist days. 2017 April 21, Maastricht, the Netherlands

Van der Hilst J. (in)appropriate use of antibiotics in traveller's diarrhoea. 15th Conference of the International Society of Travel Medicine. 2017 May 14-18, Barcelona, Spain

Van der Hilst J. Efficacy of anti-IL-1 treatment in Familial Mediterranean Fever. 9th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases. May 2017 Cyprus

Ozen S, Koné-Paut I, Hofer M, van Der Hilst J *et al.* Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With colchicine-resistant FMF: Results From the Phase 3 CLUSTER Trial. 24th Pediatric Rheumatology Congress. September 2017. Athens, Greece

Van der Hilst J. The Travelers diarrhea study. 12th National Seminar on Travel Medicine. January 25 2018, Brussels, Belgium

Miscellaneous

August-December 1999	Introduction to immunological research. Institute for inflammation research, Copenhagen, Denmark
January-April 2002	Study on the influence of PPAR γ agonist pioglitazon on monocyte adhesion in patients with type 2 diabetes. UMC Utrecht, the Netherlands
September-October 2004	Project on in vitro systems of amyloidosis. Prof. Benson, Indianapolis, USA
2008- 2014	Member editorial board of Amyloid: the Journal of Protein Folding Disorders
2010	Scientific committee Auto-inflammation 2010 6 th international congress of FMF and SAID, 2-6 September 2010, Amsterdam, the Netherlands
2012-present	Section editor case reports, Tijdschrift voor Geneeskunde, Leuven, Belgium
2015-present	Member of the scientific study group for travel medicine
2015-present	Founder and Chair of the Belgian Network for Autoinflammatory diseases
2015-2017	Member of the steering committee for rare diseases, Koning Boudewijnstichting.
Dec 2016	Organizing committee 'IL-1 mediated Autoinflammation: from molecular pathogenesis to clinical treatment' Joint symposium of the Interuniversitaire werkgroep autoinflammatoire ziekten and the BNAID, December 1 st 2016, Utrecht, Netherlands
2016-2017	Management for health care professionals, Vlerick Business School
2017-present	Mandated Member Belgian Primary Immunodeficiency Group